|Bid||6.87 x 1200|
|Ask||7.32 x 1000|
|Day's range||6.60 - 6.88|
|52-week range||3.28 - 9.13|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.27|
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
To get a sense of who is truly in control of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), it is important to understand...
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.